The AI-driven medical device CAD software has been developed by Bot Image.

Bot Image has developed an AI tool called ProstatID that combines AI with MRI scans to improve the detection and diagnosis of prostate cancer. According to Cancer.Net, prostate cancer is the most common cancer among men, except for skin cancer. This year, an estimated 268,490 men in the United States will be diagnosed with prostate cancer.

The AI-driven medical CAD software has been trained on thousands of MRI image sets, radiological interpretations, guided biopsies, and pathology lab results. Its algorithm recognizes and measures the volume of the prostate gland, and detects suspicious cancerous lesions – assigning a cancer probability to each one, and suggests a diagnostic case score known as PI-RADS (Prostate Imaging Reporting and Data System) score.

When tested in clinical studies the tool was shown to significantly improve radiologic interpretation accuracy as measured by improved detection and fewer false positives.

ProstatID

The computer-aided design tool is currently available for use as a Software-as-a-service (SaaS) device which connects the radiology department server or MRI system to the cloud-based ProstatID server through VPN.

“Prostate cancer screening and detection methods adoption has changed little over the past 30 years, despite the mountain of evidence pointing to the efficacy of superior technologies and the futility of the old methods,” says the company founder and CEO Dr. Randall W. Jones. “Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the US alone. ProstatID represents an exciting step in the fight to save lives.”

Now that FDA has cleared ProstatID, hospitals and radiological clinics can connect in as little as one hour of IT effort to implement the tool.

Related Story: FDA Clears AI-Powered Tool From Paige To Detect Prostate Cancer